CUE
Cue Biopharma, Inc. · Healthcare
Insiders bought $100K of Cue Biopharma, Inc. in the last 12 months
CUE over the last year
CUE after insider buys
3 months after each buy, from the first price a copier could get.
4 buys since 2018 with 3 months of prices.
Every filing
39 insider filings since 2018, newest first
Sumita Ray · Chief Legal Compliance Officer
Michael Vincent Meluzio · VP, Prin. Accounting Officer
Shao-Lee Lin · Chief Executive Officer
Sumita Ray · Chief Legal Compliance Officer
Michael Vincent Meluzio · VP, Prin. Accounting Officer
Shao-Lee Lin · Chief Executive Officer
Pasha Sarraf · Director
Daniel R Passeri · CEO
Peter A Kiener · Director
Aaron G.l. Fletcher · Director
Peter A Kiener · Director
Anish Suri · President and CSO
Anish Suri · President and CSO
Anish Suri · President and CSO
Daniel R Passeri · CEO
Kenneth Pienta · Chief Medical Officer
Kenneth Pienta · Chief Medical Officer
Kenneth Pienta · Chief Medical Officer
Cameron Gray · Director
Colin Sandercock · SVP, GC, Sec
Colin Sandercock · SVP, GC, Sec
Anish Suri · President and CSO
Colin Sandercock · SVP, GC, Sec
Christopher A Marlett · Director
Christopher A Marlett · Director
Christopher A Marlett · Director
Colin Sandercock · SVP, GC, Sec
Christopher A Marlett · Director
Anthony Digiandomenico · Director
Anthony Digiandomenico · Director
Christopher A Marlett · Director
Christopher A Marlett · Director
Anthony Digiandomenico · Director
Christopher A Marlett · Director
Anthony Digiandomenico · Director
Christopher A Marlett · Director
Christopher A Marlett · Director
Christopher A Marlett · Director
Daniel R Passeri · CEO and President
About Cue Biopharma, Inc.
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.